Dobutamine hydrochloride
Tocris Bioscience, part of Bio-Techne | Catalog # 0515
α1, β1 and β2 agonist
Key Product Details
Description
α1, β1 and β2 agonist
Product Description
Dobutamine hydrochloride is a β1- and β2-adrenoceptor agonist with some action at the α1-adrenoceptor.Product Specifications
Molecular Weight
337.85
Formula
C18H23NO3.HCl
Storage
Desiccate at RT
Purity
≥98% (HPLC)
Chemical Name
4-[2-[[3-(4-Hydroxyphenyl)-1-methylpropyl]aminoethyl-1,2-benzenediol hydrochloride
CAS Number
49745-95-1
PubChem ID
65324
InChI Key
BQKADKWNRWCIJL-UHFFFAOYSA-N
SMILES
Cl.CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 33.78 | 100 |
Preparing Stock Solutions
for Dobutamine hydrochloride
The following data is based on the product molecular weight 337.85
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.96 mL | 14.80 mL | 29.60 mL |
| 5 mM | 0.59 mL | 2.96 mL | 5.92 mL |
| 10 mM | 0.30 mL | 1.48 mL | 2.96 mL |
| 50 mM | 0.06 mL | 0.30 mL | 0.59 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Deighton Characterization of the beta adrenoceptor subtype(s) mediating the positive inotropic effects of epinine, DA, dobutamine, denopamine and xamoterol in isolated human right atrium. J.Pharmacol.Exp.Ther. 1992 PMID: 1354251
- Brown Dobutamine: positive inotropy by nonselective adrenoceptor agonism in isolated guinea pig and human myocardium. Naunyn Schmiedebergs Arch.Pharmacol. 1987 PMID: 3600817
Product Specific Notices for Dobutamine hydrochloride
For research use only
Loading...
Loading...